Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast ; day:20 ; month:4 ; year:2024 ; pages:1-11
Advances in therapy ; (20.4.2024), 1-11
- Creator
-
Costa, Luciano J.
Rodriguez-Otero, Paula
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02842-9
- URN
-
urn:nbn:de:101:1-2407022100427.450502153130
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Costa, Luciano J.
- Rodriguez-Otero, Paula
- SpringerLink (Online service)
Other Objects (12)
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
ASH highlights 2022—multiple myeloma
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
ASH 2018—Highlights in Multiple Myeloma
Multiple myeloma: my highlights at ASH 2020
Accelerated single cell seeding in relapsed multiple myeloma
Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
VolcAshDB: a Volcanic Ash DataBase of classified particle images and features
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
ASH highlights 2022—multiple myeloma
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
ASH 2018—Highlights in Multiple Myeloma
Multiple myeloma: my highlights at ASH 2020
Accelerated single cell seeding in relapsed multiple myeloma
Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
VolcAshDB: a Volcanic Ash DataBase of classified particle images and features
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
ASH highlights 2022—multiple myeloma
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
ASH 2018—Highlights in Multiple Myeloma
Multiple myeloma: my highlights at ASH 2020
Accelerated single cell seeding in relapsed multiple myeloma
Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
VolcAshDB: a Volcanic Ash DataBase of classified particle images and features